secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALLURION TECHNOLOGIES, INC. (ALUR)
CIK:        0001964979
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0001193125-25-026187
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allurion relaunches balloon in France after ANSM clearance; exploring combo GLP-1 trial
--------------------------------------------------------------------------------

- ANSM cleared Allurion to resume sales of Allurion Balloon in France, effective immediately (Feb 13, 2025).
- France historically represented approximately 15% of Allurion's revenue.
- Company plans clinical trial combining balloon with GLP-1s to study prevention of muscle loss during GLP-1 therapy.
- Previous study: patients with balloon gained 5.6% lean body mass while losing 14% total weight over 4 months.
- Another study: 167 patients lost 15.7% weight with no change in muscle mass.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1964979/000119312525026187/0001193125-25-026187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1964979/000119312525026187/d826753d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-026187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer